(CLBT) Cellebrite DI - Ratings and Ratios

Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: IL0011794802

Digital Forensics, Extraction, Analysis, Case Management, Training

Application Software
Market Cap in USD: 4,486m
IPO / Inception: 2021-08-31
12m vs SPY: -34.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of CLBT over the last years for every Quarter: "2020-12": -0.2013, "2021-03": 0.22, "2021-06": 0.05, "2021-09": 0.08, "2021-12": 0.03, "2022-03": 0.01, "2022-06": 0.17, "2022-09": 0.01, "2022-12": 0.08, "2023-03": 0.03, "2023-06": 0.05, "2023-09": 0.09, "2023-12": 0.12, "2024-03": 0.08, "2024-06": 0.1, "2024-09": 0.14, "2024-12": 0.1, "2025-03": 0.1, "2025-06": 0.12, "2025-09": 0.14,
EPS CAGR: 50.80%
EPS Trend: 64.5%
Last SUE: 0.44
Qual. Beats: 0

Revenue

Revenue of CLBT over the last years for every Quarter: 2020-12: 57.168, 2021-03: 53.283, 2021-06: 59.168, 2021-09: 65.887, 2021-12: 67.908, 2022-03: 62.385, 2022-06: 62.573, 2022-09: 71.675, 2022-12: 74.018, 2023-03: 71.234, 2023-06: 76.684, 2023-09: 84.179, 2023-12: 93.013, 2024-03: 89.582, 2024-06: 95.714, 2024-09: 106.858, 2024-12: 109.049, 2025-03: 107.549, 2025-06: 113.276, 2025-09: 126.029,
Rev. CAGR: 17.93%
Rev. Trend: 97.6%
Last SUE: 1.10
Qual. Beats: 1

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 40.2%
Value at Risk 5%th 58.3%
Relative Tail Risk -11.83%
Reward TTM
Sharpe Ratio -0.39
Alpha -34.93
CAGR/Max DD 1.22
Character TTM
Hurst Exponent 0.414
Beta 0.705
Beta Downside 0.596
Drawdowns 3y
Max DD 48.00%
Mean DD 13.43%
Median DD 6.83%

Description: CLBT Cellebrite DI January 11, 2026

Cellebrite DI Ltd. (NASDAQ: CLBT) builds software platforms that enable legally sanctioned investigations across the globe, covering the full forensic lifecycle-from data acquisition and decoding to analysis, visualization, and case management. Its flagship products include Inseyets for evidence collection, Pathfinder for automated analysis, Smart Search for open-source intelligence, and Guardian for evidence management, with enterprise-focused extensions such as Endpoint Inspector and Endpoint Mobile Now.

In FY 2023 the company reported revenue of roughly $210 million, a year-over-year increase of about 15%, and an operating margin near 18%, reflecting strong demand from law-enforcement agencies and corporate security units. The digital-forensics market is expanding at a compound annual growth rate of 12-14% driven by rising cyber-crime incidents, stricter data-privacy regulations, and increasing budgets for investigative technology in both the public and private sectors.

For a deeper quantitative comparison, you might explore ValueRay’s analyst toolkit to benchmark Cellebrite’s performance against peers.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (76.3m TTM) > 0 and > 6% of Revenue (6% = 27.4m TTM)
FCFTA 0.17 (>2.0%) and ΔFCFTA 0.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 77.10% (prev 59.33%; Δ 17.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.18 (>3.0%) and CFO 152.7m > Net Income 76.3m (YES >=105%, WARN >=100%)
Net Debt (-259.9m) to EBITDA (77.4m) ratio: -3.36 <= 3.0 (WARN <= 3.5)
Current Ratio 2.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (249.7m) change vs 12m ago 19.65% (target <= -2.0% for YES)
Gross Margin 83.96% (prev 84.45%; Δ -0.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 62.30% (prev 61.21%; Δ 1.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 49.44 (EBITDA TTM 77.4m / Interest Expense TTM 1.35m) >= 6 (WARN >= 3)

Altman Z'' 4.17

(A) 0.42 = (Total Current Assets 668.4m - Total Current Liabilities 316.9m) / Total Assets 834.3m
(B) -0.13 = Retained Earnings (Balance) -107.8m / Total Assets 834.3m
(C) 0.09 = EBIT TTM 66.7m / Avg Total Assets 731.8m
(D) 1.16 = Book Value of Equity 447.8m / Total Liabilities 386.6m
Total Rating: 4.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.63

1. Piotroski 6.0pt
2. FCF Yield 3.49%
3. FCF Margin 30.51%
4. Debt/Equity 0.05
5. Debt/Ebitda -3.36
6. ROIC - WACC (= 5.76)%
7. RoE 19.63%
8. Rev. Trend 97.61%
9. EPS Trend 64.48%

What is the price of CLBT shares?

As of January 15, 2026, the stock is trading at USD 17.55 with a total of 966,884 shares traded.
Over the past week, the price has changed by -6.55%, over one month by -1.68%, over three months by -9.77% and over the past year by -21.23%.

Is CLBT a buy, sell or hold?

Cellebrite DI has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy CLBT.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CLBT price?

Issuer Target Up/Down from current
Wallstreet Target Price 24.7 40.8%
Analysts Target Price 24.7 40.8%
ValueRay Target Price 22.4 27.6%

CLBT Fundamental Data Overview January 10, 2026

P/E Trailing = 48.2895
P/E Forward = 37.1747
P/S = 9.8398
P/B = 10.0205
Revenue TTM = 455.9m USD
EBIT TTM = 66.7m USD
EBITDA TTM = 77.4m USD
Long Term Debt = 21.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.62m USD (from shortTermDebt, last quarter)
Debt = 21.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -259.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.98b USD (4.49b + Debt 21.4m - CCE 525.7m)
Interest Coverage Ratio = 49.44 (Ebit TTM 66.7m / Interest Expense TTM 1.35m)
EV/FCF = 28.62x (Enterprise Value 3.98b / FCF TTM 139.1m)
FCF Yield = 3.49% (FCF TTM 139.1m / Enterprise Value 3.98b)
FCF Margin = 30.51% (FCF TTM 139.1m / Revenue TTM 455.9m)
Net Margin = 16.74% (Net Income TTM 76.3m / Revenue TTM 455.9m)
Gross Margin = 83.96% ((Revenue TTM 455.9m - Cost of Revenue TTM 73.1m) / Revenue TTM)
Gross Margin QoQ = 83.88% (prev 84.39%)
Tobins Q-Ratio = 4.77 (Enterprise Value 3.98b / Total Assets 834.3m)
Interest Expense / Debt = 6.29% (Interest Expense 1.35m / Debt 21.4m)
Taxrate = 16.88% (4.10m / 24.3m)
NOPAT = 55.4m (EBIT 66.7m * (1 - 16.88%))
Current Ratio = 2.11 (Total Current Assets 668.4m / Total Current Liabilities 316.9m)
Debt / Equity = 0.05 (Debt 21.4m / totalStockholderEquity, last quarter 447.7m)
Debt / EBITDA = -3.36 (Net Debt -259.9m / EBITDA 77.4m)
Debt / FCF = -1.87 (Net Debt -259.9m / FCF TTM 139.1m)
Total Stockholder Equity = 388.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.43% (Net Income 76.3m / Total Assets 834.3m)
RoE = 19.63% (Net Income TTM 76.3m / Total Stockholder Equity 388.9m)
RoCE = 16.25% (EBIT 66.7m / Capital Employed (Equity 388.9m + L.T.Debt 21.4m))
RoIC = 14.26% (NOPAT 55.4m / Invested Capital 388.9m)
WACC = 8.49% (E(4.49b)/V(4.51b) * Re(8.51%) + D(21.4m)/V(4.51b) * Rd(6.29%) * (1-Tc(0.17)))
Discount Rate = 8.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.33%
[DCF Debug] Terminal Value 79.67% ; FCFF base≈123.0m ; Y1≈151.7m ; Y5≈258.4m
Fair Price DCF = 17.29 (EV 3.97b - Net Debt -259.9m = Equity 4.23b / Shares 244.5m; r=8.49% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 64.48 | EPS CAGR: 50.80% | SUE: 0.44 | # QB: 0
Revenue Correlation: 97.61 | Revenue CAGR: 17.93% | SUE: 1.10 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=-0.005 | Revisions Net=-2 | Analysts=6
EPS next Year (2026-12-31): EPS=0.55 | Chg30d=+0.027 | Revisions Net=+7 | Growth EPS=+7.7% | Growth Revenue=+17.2%

Additional Sources for CLBT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle